In this line,recent studies using mouse models of muscular dystrophies affecting dystrophin–glycoproteincomplex have shown that increasing SERCA activity either by inducing HSP72 expression (Ref.13), or through SERCA1 and SERCA2 overexpressionusing transgenic mice and adeno-associated virus gene therapy (Ref. This evidence concerns the gene DMD and muscular dystrophy.